US Alzheimer's Disease Drug Market, Dosage, Price and Clinical Trials Insight 2026

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

"US Alzheimer's Disease Drug Market, Dosage, Price and Clinical Trials Insight 2026" Report Highlights:

US Alzheimer's Disease Drug Market Opportunity: > US$ 5 Billion
US Accounts For More Than 40% of Global Alzheimer's Disease Drug Market
US Alzheimer's Disease Drug Clinical Trials: 200 Drugs in Pipeline
US Alzheimer's Disease Drug Availability: 9 Branded and Several Generics
Clinical Insight on 200 Alzheimer's Disease Drug in Pipeline
Marketed Branded/Generis/ Drugs Dosage, Patent, Price Insight
420 Page Comprehensive Insight on Clinical and Commercial Market Landscape

Alzheimer’s disease is a neurodegenerative disorder that leads to difficulty in walking and memorizing things. The US among all the other countries in the world is showing promising opportunities to the growing Alzheimer’s disease market as the country is witnessing large number of patients getting diagnosed with the disease. The US Alzheimer’s disease drug market is set to focus on the complete transformation of the market towards a sector where prioritizing healthcare for the patients is only the aim of the researchers. Although the market has achieved all the set goals for Alzheimer’s disease have been achieved long back but still the market is progressing towards establishing novel goals for driving the future of the market.

The US Alzheimer’s disease drug market is symbiotically and synergistically moving towards introducing innovative technologies and devices for building several different novel operating models for the disease market future. It can be witnessed for US Alzheimer’s disease therapeutics market that the initial growth trend for the market when compared with the current growth trend is completely different. In a very few years of time period, the market has been transformed by the protocols that were followed for the development of the drugs and therapies as well as different regulatory processes that made the entire procedure of drug approval difficult. In addition to it, the market is highly supported by other important parameters such as introduction of number of therapies for the patient population, increase in geriatric population in the country and technologically driven clinical research studies.

The market is now affiliated with increase in the number of launches, which is estimated to shift the market towards approximately 50% growth in the next few years. Alzheimer’s drugs in the country also represents more than 50% of the medicines available for dementia conditions, thus making the entire market of Alzheimer’s disease the largest contributor of the dementia market. In addition to it, the market is supported by high drug research designations and breakthrough discoveries that will make the market appreciate more when compared to other dementia markets in the country.

It can be well-witnessed for the US Alzheimer’s disease drug market that the overall research and development sector of the market has accelerated at a very high rate and also in a prominent way. All the drugs and therapies that are available in the market are made to achieve and respond to critical advanced stage of the disease. The overall progress observed in the market is reflected by the strong and robust clinical pipeline that it is holding for long period of time.

As per "US Alzheimer's Disease Drug Market, Dosage, Price and Clinical Trials Insight 2026" report findings, it is estimated that the US Alzheimer’s disease therapeutics market will be over-shadowing the growing trends and opportunities that can be observed for other emerging markets of the world. The availability of hundreds of blockbuster drugs for the patient population and robust clinical pipeline in the US research firms and bio-pharmaceutical companies are estimated to boost the overall market growth tractions. The current Alzheimer’s disease therapeutics market is now looking forward to undergo important and novel functional collaborations and partnerships that will ultimately lead to outsourcing of hundreds of novel drugs, diagnostic tools and therapies for US patient population as well as for global patients. The future share of the Alzheimer’s disease therapeutics market is estimated to increase at a very high rate, which will eventually strengthen the entire dominance level of US at global level. Hundreds of novel investments for the development of the market is also holding promise to advance the entire market scenario and market trends that will support high-quality drugs for future patients.

US Alzheimer's Disease Drug Market Overview

US - Approved Alzheimer's Disease Drugs by Class

2.1 Cholinesterase Inhibitors

2.2 NMDA Receptor Agonist

US - New Emerging Therapies in Alzheimer's Disease

3.1 Monoclonal Antibody

3.2 Novel NMDA Receptor Agonists

3.3 Small Molecules Drug

3.4 Oral Semaglutide

US - Alzheimer's Disease Generic and Biosimilar Drug Market Landscape

4.1 Current Scenario and Price Differential

4.2 Reimbursement Laws and Regulations

Anti-Alzheimer’s Disease Drugs Classification

Acetylcholinesterases Inhibitor: US Market Availability, Dosage, Patent and Price Insight

6.1 Razadyne (Brand Drug)

6.2 Razadyne ER (Branded)

6.3 Aricept (Brand Drug)

6.4 Aricept ODT (Branded)

6.5 Reminyl (Branded)

6.6 Exelon (Brand Drug)

6.7 Namzaric (Brand Drug)

N-methyl-D-aspartate Inhibitors: US Market Availability, Dosage, Patent and Price Insight

7.1 Namenda (Brand Drug)

7.2 Namenda XR (Branded)

Approved Generic Drugs fo Alzheimer's: US Market Availability, Dosage and Price Insight

8.1 Galantamine (Generic Drug)

8.2 Donepzil (Generic Drug)

8.3 Rivastigmine (Generic Drug)

8.4 Memantine (Generic Drug)

8.5 Ergoloid Mesylates

US - Alzheimer's Disease Drugs Clinical Trials Overview

9.1 By Biomarket

9.2 By Formulation

9.3 By Organization

9.4 By Phase

9.5 By Patient Segment

US - Alzheimer’s Disease Drug Clinical Pipeline By Company, Indication and Phase

10.1 Unknown

10.2 Research

10.3 Preclinical

10.4 Clinical

10.5 Phase-I

10.6 Phase-I/II

10.7 Phase-II

10.8 Phase-II/III

10.9 Phase-III

10.10 Preregistration

10.11 Registered

US - Marketed Alzheimer’s Disease Drugs Clinical Insight

11.1 Razadyne

11.2 Namenda

11.3 Exelon Patch

11.4 Amyvid

11.5 Namzaric

11.6 Aricept

11.7 NeuraCeq

11.8 Vizamyl

11.9 Cognex

US Alzheimer's Disease Drug Market Dynamics

12.1 US Alzheimer's Market Favourable Parameters

12.2 US Alzheimer's Drug Market Challenges

US Alzheimer Drug Market Future Prospects

Competitive Landscape

14.1 Allergan

14.2 Alvogen

14.3 Dr. Reddy Laboratories

14.4 Eisai Co Ltd

14.5 Hoffmann- La Roche Ltd

14.6 Jassen Pharmaceuticals

14.7 Lupin

14.8 Mylan

14.9 Novartis AG

14.10 Sun Pharma

14.11 Teva Pharmaceuticals

Figure 1-1: US- Alzheimer's Disease Cases (Million) by Age, 2020

Figure 1-2: US - Alzheimer's Disease Expected Cases by Age(%), 2020

Figure 1-3: US - Alzheimer Drug Market Oppotunity (US$ Billion), 2020 - 2026

Figure 1-4: Alzheimer's Drugs – Clinical Pipeline, 2020

Figure 2 -1: Acetylcholinesterase Inhibitors – Mechanism of Action

Figure 2-2: Memantine – Mode of Action

Figure 3-1: Designed Monoclonal Antibodies for Alzheimer Disease Discontinued Till Phase-3 Trials

Figure 4-1: US - Alzheimer's Disease Estimated Cost of Treatment (US$ Billion), 2020

Figure 4-2: Aricept and Donepezil - Cost per Unit (US$ )

Figure 4-3: Namenda and Memantine - Cost per Unit (US$)

Figure 4-4: Namenda and Memantine – Annual Sales (US$ Million), 2019

Figure 4-5: US - Total Cost Care of Alzheimer's Treatment (US$ Billion), 2020

Figure 4-6: US - Alzheimer's Disease In-Pocket Cost and Out-Pocket Cost (%), 2020

Figure 5-1: Drugs for the Alzheimer’s Disease

Figure 6-1: Razadyne – FDA Approval and First Generic Approval Year

Figure 6-2: Razadyne – Cost of 60 Tablets of Dosage 4 mg (US$), January’2021

Figure 6-3: Razadyne – Cost of 60 Tablets of Dosage 8 mg (US$), January’2021

Figure 6-4: Razadyne – Cost of 60 Tablets of Dosage 12 mg (US$), January’2021

Figure 6-5: Razadyne– Price of 100ml Supply and Price per unit ml of Oral Solution (US$), January’2021

Figure 6 -6: Razadyne – Recommended Initial Dose and Incremented Dose (mg/day), January’2021

Figure 6-7: Razadyne – Patent Issue and Patent Expiration by US FDA

Figure 6-8: Razadyne ER – FDA Approval and First Generic Approval Year

Figure 6-9: Razadyne ER – Cost of 30 Tablets of Various Dose Regimens (US$), January’2021

Figure 6-10: Razadyne ER – Recommended Initial Dose and Incremented Dose (mg/day), January’2021

Figure 6-11: Aricept – FDA Approval Year by Dosage Forms

Figure 6-12: Aricept – Price of 30 Tablets of 5mg Drug (US$), January’2021

Figure 6-13: Aricept – Price of 21 Tablets of 10mg Drug (US$), January’2021

Figure 6-14: Aricept – Minimum Price of 30 Tablets of 10mg Drug (US$), January’2021

Figure 6-15: Aricept – Maximum Price of 30 Tablets of 10mg Drug (US$), January’2021

Figure 6-16: Aricept – Price of 30 Tablets of 23mg Drug (US$), January’2021

Figure 6-17: Aricept – Recommended and Incremented Dose for Alzheimer’s Disease (mg/day)

Figure 6-18: Aricept – Time Interval for 1st and 2nd Dose Increment (Weeks)

Figure 6-19: Aricept ODT – Cost of 30 Tablets of Dosage 5 mg (US$), January’2021

Figure 6-20: Aricept ODT – Cost of 30 Tablets of Dosage 10 mg (US$), January’2021

Figure 6-21: Aricept ODT – Recommended Initial and Incremented Dose (mg/day)

Figure 6-22: Aricept ODT – Time Interval Required for Dose Increment (Weeks)

Figure 6-23: Reminyl – USFDA and PMDA Approval Year

Figure 6-24: Reminyl – FDA Approval Year by Dosage Forms

Figure 6-25: Reminyl – Cost of 100ml and Price per ml of Oral Solution (US$), January’2021

Figure 6-26: Reminyl – Cost of 56 Tablet and Price per Tablet of 8mg and 12 mg Dose (US$), January’2021

Figure 6-27: Reminyl – Cost of 112 Tablet and Price per Tablet of 8mg (US$), January’2021

Figure 6-28: Reminyl – Recommended Initial and Incremented Dose (mg/day)

Figure 6-29: Exelon – US FDA and Europe EMEA Approval Year

Figure 6-30: Exelon – FDA Approval Year by Dosage Forms

Figure 6-31: Exelon – Price of 30 Transdermal Films of Dose 4.6 mg/24 hr (US$), January’2021

Figure 6-32: Exelon – Price of 30 Transdermal Films of Dose 9.5 mg/24 hr (US$), January’2021

Figure 6-33: Exelon – Price of 30 Transdermal Films of Dose 13.3 mg/24 hr (US$), January’2021

Figure 6-34: Exelon – Recommended Initial and Incremented Dose (mg/24 Hours)

Figure 6-35: Namzaric – FDA Approval Year by Dose

Figure 6-36: Namzaric – Forest Laboratory’s Patent Issue and Expiration Year

Figure 6-37: Namzaric – Adamas Pharmaceutical’s Patent Issue and Expiration Year

Figure 6-38: Namzaric – Price of 30 Capsules of the Drug of Dosage 7 mg – 10 mg (US$), January’2021

Figure 6-39: Namzaric – Price of 30 Capsules of the Drug of Dosage 10 mg – 14 mg (US$), January’2021

Figure 6-40: Namzaric – Price of 30 Capsules of the Drug of Dosage 10 mg – 21 mg (US$), January’2021

Figure 6-41: Namzaric – Price of 30 Capsules of the Drug of Dosage 10 mg – 28 mg (US$), January’2021

Figure 6-42: Namzaric – Recommended Initial and Incremented Dose Based on Memantine Administration (mg/day)

Figure 7-1: Namenda – FDA Approval Year by Dosage Forms

Figure 7-2: Namenda – FDA Approval and First Generic Approval Year

Figure 7-3: Namenda - Price of 49 Oral Kits (US$), January’2021

Figure 7-4: Namenda - Price of 60 Oral Tablets of Dosage 5mg (US$), January’2021

Figure 7-5: Namenda - Price of 100 Oral Tablets of Dosage 5mg (US$), January’2021

Figure 7-6: Namenda - Price of 60 Oral Tablets of Dosage 10mg (US$), January’2021

Figure 7-7: Namenda - Price of 100 Oral Tablets of Dosage 10mg (US$), January’2021

Figure 7-8: Namenda – Recommended Initial and Incremented Dose (mg/day)

Figure 7-9: US – Namenda Sales (US$ Million), 2016 - 2018

Figure 7-10: Namenda XR – FDA Approval and First Generic Approval Year

Figure 7-11: Namenda XR – Forest Laboratory’s Patent Issue and Expiration Year

Figure 7-12: Namzaric – Adamas Pharmaceutical’s Patent Issue and Expiration Year

Figure 7-13: Namenda XR – Price of 30 Capsules Supply of Various Dose Regimen (US$), January’2021

Figure 7-14: Namenda XR – Price of 90 Capsules Supply of 14mg and 28 mg Dose Regimen (US$), January’2021

Figure 7-15: Namenda XR Kit – Price of 28 Kit Supply and Price per unit Kit (US$), January’2021

Figure 7-16: Namenda XR – Recommended Initial and Incremented Dose (mg/day)

Figure 8-1: Galantamine (Generic Drug) – Cost of 30 capsules of Dosage 8 mg (US$), January’2021

Figure 8-2: Galantamine (Generic Drug) – Cost of 30 capsules of Dosage 16 mg (US$), January’2021

Figure 8-3: Galantamine (Generic Drug) – Cost of 30 capsules of Dosage 24 mg (US$), January’2021

Figure 8-4: Galantamine (Generic Drug) – Cost of 100 ml of Dosage 4 mg/ml (US$), January’2021

Figure 8-5: Galantamine (Generic Drug) – Cost of 30 Tablets of 4mg Dosage (US$), January’2021

Figure 8-6: Galantamine (Generic Drug) – Cost of 30 Tablets of 4mg Dosage (US$), January’2021

Figure 8-7: Galantamine (Generic Drug) – Cost of 60 Tablets of 4mg Dosage (US$), January’2021

Figure 8-8: Galantamine (Generic Drug) – Cost of 60 Tablets of 4mg Dosage (US$), January’2021

Figure 8-9: Galantamine (Generic Drug) – Cost of 30 Tablets of 8 mg Dosage (US$), January’2021

Figure 8-10: Galantamine (Generic Drug) – Cost of 30 Tablets of 8 mg Dosage (US$), January’2021

Figure 8-11: Galantamine (Generic Drug) – Cost of 60 Tablets of 8 mg Dosage (US$), January’2021

Figure 8-12: Galantamine (Generic Drug) – Cost of 60 Tablets of 8 mg Dosage (US$), January’2021

Figure 8-13: Galantamine (Generic Drug) – Cost of 60 Tablets of 12 mg Dosage (US$), January’2021

Figure 8-14: Galantamine (Generic Drug) – Cost of 60 Tablets of 12 mg Dosage (US$), January’2021

Figure 8-15: Galantamine Tablet and Solution – Recommended Initial and Incremented Dose (mg/day), January’2021

Figure 8-16: Galantamine ER – Recommended Initial Dose and Incremented Dose (mg/day), January’2021

Figure 8-17: Donepzil – Price of 30 Tablets of 5 mg Drug (US$), January’2021

Figure 8-18: Donepzil – Price of 30 Tablets of 10 mg Drug (US$), January’2021

Figure 8-19: Donepzil – Price of 90 Tablets of 5 mg Drug (US$), January’2021

Figure 8-20: Donepzil – Price of 100 (10X10 each) Tablets of 5 mg Drug (US$), January’2021

Figure 8-21: Donepzil – Price of 90 Tablets of 10 mg Drug (US$), January’2021

Figure 8-22: Donepzil – Price of 100 Tablets of 10 mg Drug (US$), January’2021

Figure 8-23: Donepzil – Price of 30 Tablets of 23 mg Drug (US$), January’2021

Figure 8-24: Donepzil – Price of 90 Tablets of 23 mg Drug (US$), January’2021

Figure 8-25: Donepzil – Price of 28 (4X7 each) Tablets of 5 mg Drug Disintegrating (US$), January’2021

Figure 8-26: Donepzil – Price of 30 Tablets of 5 mg Drug Disintegrating (US$), January’2021

Figure 8-27: Donepzil – Price of 28 (4X7 each) Tablets of 10 mg Drug Disintegrating (US$), January’2021

Figure 8-28: Donepzil – Price of 30 Tablets of 10 mg Drug Disintegrating (US$), January’2021

Figure 8-29: Donepzil – Recommended and Incremented Dose for Alzheimer’s Disease (mg/day)

Figure 8-30: Donepzil – Time Interval for 1st and 2nd Dose Increment (Weeks)

Figure 8-31: Rivastigmine – Price of 60 Oral Capsules of Dosage 1.5 mg (US$), January’2021

Figure 8-32: Rivastigmine – Price of 100 (10X10) Oral Capsules of Dosage 1.5 mg (US$), January’2021

Figure 8-33: Rivastigmine – Price of 500 Oral Capsules of Dosage 1.5 mg (US$), January’2021

Figure 8-34: Rivastigmine – Price of 60 Oral Capsules of Dosage 3 mg (US$), January’2021

Figure 8-35: Rivastigmine – Price of 100 (10x10) Oral Capsules of Dosage 3 mg (US$), January’2021

Figure 8-36: Rivastigmine – Price of 500 Oral Capsules of Dosage 3 mg (US$), January’2021

Figure 8-37: Rivastigmine – Price of 60 Oral Capsules of Dosage 4.5 mg (US$), January’2021

Figure 8-38: Rivastigmine – Price of 100 Oral Capsules of Dosage 4.5 mg (US$), Janaury’2021

Figure 8-39: Rivastigmine – Price of 500 Oral Capsules of Dosage 4.5 mg (US$), January’2021

Figure 8-40: Rivastigmine – Price of 60 Oral Capsules of Dosage 6 mg (US$), January’2021

Figure 8-41: Rivastigmine – Price of 60 Oral Capsules of Dosage 6 mg (US$), January’2021

Figure 8-42: Rivastigmine – Price of 100 (10X10 each) Oral Capsules of Dosage 6 mg (US$), January’2021

Figure 8-43: Rivastigmine – Price of 500 Oral Capsules of Dosage 6 mg (US$), January’2021

Figure 8-44: Rivastigmine Oral – Recommended Initial and Incremented Dose (mg/day)

Figure 8-45: Rivastigmine Patch– Recommended Initial and Incremented Dose (mg/24 Hours)

Figure 8-46: Memantine – Price of 30 Capsules of Dosage 7 mg (US$), January’2021

Figure 8-47: Memantine – Price of 100 Capsules of Dosage 7 mg (US$), January’2021

Figure 8-48: Memantine – Price of 30 Capsules of Dosage 14 mg (US$), January’2021

Figure 8-49: Memantine – Price of 90 Capsules of Dosage 14 mg (US$), January’2021

Figure 8-50: Memantine – Price of 100 Capsules of Dosage 14 mg (US$), January’2021

Figure 8-51: Memantine – Price of 30 Capsules of Dosage 21 mg (US$), January’2021

Figure 8-52: Memantine – Price of 100 Capsules of Dosage 21 mg (US$), January’2021

Figure 8-53: Memantine – Price of 30 Capsules of Dosage 28 mg (US$), January’2021

Figure 8-54: Memantine – Price of Oral Kit for 49 (US$), January’2021

Figure 8-55: Memantine - Price of 200 ml (40 X 5 ml) of Oral Solution of Dosage 2 mg/ml (US$), January’2021

Figure 8-56: Memantine - Price of 240 ml of Oral Solution of Dosage 2 mg/ml (US$), January’2021

Figure 8-57: Memantine - Price of 360 ml of Oral Solution of Dosage 2 mg/ml (US$), January’2021

Figure 8-58: Memantine - Price of 50 Oral Tablets of Dosage 5 mg (US$), January’2021

Figure 8-59: Memantine - Price of 30 Oral Tablets of Dosage 10 mg (US$), January’2021

Figure 8-60: Memantine Tablet – Recommended Initial and Incremented Dose (mg/day)

Figure 8-61: Memantine XR – Recommended Initial and Incremented Dose (mg/day)

Figure 8-62: Ergoloid Mesylates – Average Price of 100 Tablets and Price per unit Tablet (US$), January’2021

Figure 8-63: Ergoloid Mesylates – Average Price of 10 Tablets and Price per unit Tablet (US$), January’2021

Figure 8-64: Ergoloid Mesylates – Daily, Monthly and Annual Treatment Cost (US$), January’2021

Figure 9-1: US - Number of Alzheimer's Drugs in Clinical Trials by Biomarker, 2021 till 2026

Figure 9-2: US - Number of Alzheimer's Drugs in Clinical Trials by Formulation, 2021 till 2026

Figure 9-3: US - Number of Alzheimer's Drugs in Clinical Trials by Organization, 2021 till 2026

Figure 9-4: US - Number of Alzheimer's Drugs in Clinical Trials by Phase, 2021 till 2026

Figure 9-5: US - Number of Alzheimer's Drugs in Clinical Trials by Patient Segment, 2021 till 2026

Figure 12-1: US Alzheimer's Drug Market Favourable Parameters

Figure 12-2: US - Alzheimer's DrugMarket Challenges

Figure 13-1: US – Alzheimer Disease Affected Individuals (Million), 2020, 2025 and 2050

Figure 13-2: US – Alzheimer Disease Patients (Million) by Gender, 2020

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

US Alzheimer's Disease Drug Market, Dosage, Price and Clinical Trials Insight 2026

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

"US Alzheimer's Disease Drug Market, Dosage, Price and Clinical Trials Insight 2026" Report Highlights:

US Alzheimer's Disease Drug Market Opportunity: > US$ 5 Billion

US Accounts For More Than 40% of Global Alzheimer's Disease Drug Market

US Alzheimer's Disease Drug Clinical Trials: 200 Drugs in Pipeline

US Alzheimer's Disease Drug Availability: 9 Branded and Several Generics

Clinical Insight on 200 Alzheimer's Disease Drug in Pipeline

Marketed Branded/Generis/ Drugs Dosage, Patent, Price Insight

420 Page Comprehensive Insight on Clinical and Commercial Market Landscape

US Alzheimer's Disease Drug Market Overview

US - Approved Alzheimer's Disease Drugs by Class

2.1 Cholinesterase Inhibitors

2.2 NMDA Receptor Agonist

US - New Emerging Therapies in Alzheimer's Disease

3.1 Monoclonal Antibody

3.2 Novel NMDA Receptor Agonists

3.3 Small Molecules Drug

3.4 Oral Semaglutide

US - Alzheimer's Disease Generic and Biosimilar Drug Market Landscape

4.1 Current Scenario and Price Differential

4.2 Reimbursement Laws and Regulations

Anti-Alzheimer’s Disease Drugs Classification

Acetylcholinesterases Inhibitor: US Market Availability, Dosage, Patent and Price Insight

6.1 Razadyne (Brand Drug)

6.2 Razadyne ER (Branded)

6.3 Aricept (Brand Drug)

6.4 Aricept ODT (Branded)

6.5 Reminyl (Branded)

6.6 Exelon (Brand Drug)

6.7 Namzaric (Brand Drug)

N-methyl-D-aspartate Inhibitors: US Market Availability, Dosage, Patent and Price Insight

7.1 Namenda (Brand Drug)

7.2 Namenda XR (Branded)

Approved Generic Drugs fo Alzheimer's: US Market Availability, Dosage and Price Insight

8.1 Galantamine (Generic Drug)

8.2 Donepzil (Generic Drug)

8.3 Rivastigmine (Generic Drug)

8.4 Memantine (Generic Drug)

8.5 Ergoloid Mesylates

US - Alzheimer's Disease Drugs Clinical Trials Overview

9.1 By Biomarket

9.2 By Formulation

9.3 By Organization

9.4 By Phase

9.5 By Patient Segment

US - Alzheimer’s Disease Drug Clinical Pipeline By Company, Indication and Phase

10.1 Unknown

10.2 Research

10.3 Preclinical

10.4 Clinical

10.5 Phase-I

10.6 Phase-I/II

10.7 Phase-II

10.8 Phase-II/III

10.9 Phase-III

10.10 Preregistration

10.11 Registered

US - Marketed Alzheimer’s Disease Drugs Clinical Insight

11.1 Razadyne

11.2 Namenda

11.3 Exelon Patch

11.4 Amyvid

11.5 Namzaric

11.6 Aricept

11.7 NeuraCeq

11.8 Vizamyl

11.9 Cognex

US Alzheimer's Disease Drug Market Dynamics

12.1 US Alzheimer's Market Favourable Parameters

12.2 US Alzheimer's Drug Market Challenges

US Alzheimer Drug Market Future Prospects

Competitive Landscape

14.1 Allergan

14.2 Alvogen

14.3 Dr. Reddy Laboratories

14.4 Eisai Co Ltd

14.5 Hoffmann- La Roche Ltd

14.6 Jassen Pharmaceuticals

14.7 Lupin